• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

by Zina | Jun 26, 2024 | News

CellTolerance™ is a unique science-based program designed with physicians and dietitians  New data presented at Digestive Disease Week 2024 reinforces the program’s unique clinical value for patients  Initiation of discussions with clinic...
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

by Zina | Jun 7, 2024 | News

All the resolutions proposed by the Board of Directors were adopted  Paris and Boston, June 7, 2024 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser...
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License

by Zina | Jun 6, 2024 | News

JV now operational to start selling products in China  Paris and Boston, June 6, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)...
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award

by Zina | May 30, 2024 | News

Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award  Prestigious international program recognizes standout digital health & medical technology products and companies  2024 awards program included more than 4,500...
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 6, 2024 and the Instructions for Participation

by Zina | May 21, 2024 | News

Paris and Boston, May 21, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the availability of...
« Older Entries

Articles récents

  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}